LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Antiphospholipid (APL) antibodies can be detected in as many as 1% to 5% of unselected individuals.1,2 These antibodies are a common acquired cause of increased thrombotic risk (currently obesity is the most common acquired cause of hypercoagulability.3-9 The term “antiphospholipid syndrome” (APS) refers to a spectrum of clinical conditions that is associated with the presence of antiphospholipid antibodies. Both clinical and laboratory features must be present for the diagnosis of APS to be made.8-10 Any one or more of the conditions discussed below can occur in patients with the antiphospholipid syndrome.
Antiphospholipid antibodies can be subclassified into several clinical categories:
A variety of therapeutic drugs can induce the production of antiphospholipid antibodies
calcium channel blockers
Individuals with drug-induced antiphospholipid antibodies that persist after the drug treatment is ended experience an increased risk of thrombosis.5
Often observed during the convalescent phase of acute bacterial and viral infection
Often observed in individuals with syphilis
Generally not associated with an increased risk of clinical complications as these antibodies tend to be directed against phospholipid rather than phospholipid-binding proteins
Note: Because it is not possible to distinguish infection-induced antiphospholipid antibodies from clinically significant antiphospholipid antibodies, all patients who test positive for antiphospholipid antibodies should be retested after 12 or more weeks to rule out transient antibodies.10
Antiphospholipid antibodies can be detected indirectly with tests that are based on their effect on clot-based, in vitro coagulation assays (ie, lupus anticoagulants) or directly by solid-phase immunoassay.13 Due to the heterogeneity of antibodies associated with APS, both clotting and solid-phase immunoassay testing is recommend when APS is suspected.4,9
1. Jenson R. The antiphospholipid antibody syndrome. Clin Hemost Rev. 2001; 15(11):1-4.
2. Misita CP, Moll S. Antiphospholipid antibodies. Circulation. 2005 Jul 19; 112(3):e39-44.PubMed 16027261
3. Triplett DA. Coagulation abnormalities. In: McClatchey KD, ed. Clinical Laboratory Medicine. 2nd ed. Baltimore, Md: Lippincott Williams and Wilkins; 2002:1033-1049.
4. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: An update. On Behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995; 74(4):1185-1190. PubMed 8560433
5. Bick RL. Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost. 2001 Oct; 7(4):241-258. PubMed 11697705
6. Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy. Heparin: A statement for healthcare professionals from the American Heart Association. 2001; 103(24):2994-3018. PubMed 11413093
7. Alving BM. The antiphospholipid syndrome: Clinical presentation, diagnosis, and patient management. In Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, Pa: WB Saunders; 2002:181-196.
8. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med.2002; 346(10):752-763. PubMed 11882732
9. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun. 2000; 15(2):163-172. PubMed 10968904
10. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost., 2006; 4(2):295-306. PubMed 16420554
11. Keeling D1, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012 Apr; 157(1):47-58.
12. Harris EN, Pierangeli SS, Gharavi AE. Diagnosis of the antiphospholipid syndrome: A proposal for use of laboratory tests. Lupus. 1998; 7(Suppl 2):S144-S148. PubMed 9814693
13. Schjetlein R, Wisloff F. An evaluation of two commercial test procedures for the detection of lupus anticoagulant. Am J Clin Pathol. 1995; 103(1):108-111. PubMed 7817935